Introduction
Antibiotics are the major risk factor for a primary episode of Clostridium difficile infection (CDI), as well as an important factor for recurrent CDI, The risk associated with antibiotics primarily relates to disruption of the protective host colonic microbiota, but may also involve selection for C, difficile strains resistant to the inciting agent.' Adjunctive therapy with probiotics has been used widely for patients with CDI, with and without the guidance of physicians. The goal of probiotic therapy is to mitigate the effects of microbiota disruption, and different mechanisms have been CoiTesponding author. E-mail address: stuart.johnson2@va.gov (S. Johnson).
proposed whereby specific probiotics affect the microbiota and interfere with C. difficile.^ Most studies of CDI prevention have focused on secondary prevention (i.e.. prevention of CDI recurrence), mainly because the risk for CDI is sufficiently high in patients with a recent CDI episode that the effect of intervention is easier to demonstrate; 20-30% after the first episode and -50% after the second episode.^ The rate of primary episode CDI among antibiotic recipients varies with different antibiotics and populations studied, but is much lower than the rate of recurrent CDI and usually is much less than 10%."* Therefore, a larger study population is needed to demonstrate efficacy in primary CDI prevention.
The efficacy of probiotics in the prevention of CDI has been hotly debated,but many studies and meta-analyses have combined primary and secondary CDI prevention data, which
